12:00 AM
May 28, 2007
 |  BioCentury  |  Emerging Company Profile

Tempo: Two-in-one approach

Differences in dosing schedules between angiogenesis inhibitors and chemotherapeutics and the fact that anti-angiogenics reduce the vasculature that delivers chemo to tumors can make optimizing the combination difficult. Tempo Pharmaceuticals Inc. believes its Nanocell drug delivery system can improve the therapeutic index of the combination by enabling timed release of two drugs within diseased tissue.

The company raised $12.1 million in a series A round last week to test Nanocell in the clinic.

Suppressing tumor growth requires long-term administration of angiogenesis inhibitors, but chemotherapy is usually given in short treatment cycles. Also, the continual administration of an anti-angiogenesis agent limits blood flow inside the tumor,...

Read the full 514 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >